Foodie Pundit

That Ospina Glyphosate Study Is Old News, Not a New FDA Rule

An FDA docket entry cites a glyphosate study based on decade-old CDC data, but it signals zero changes to grocery labels or food rules.

By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

Food service activity related to this story. Representative image.

Key points

  • Regulations.gov lists Attachment 66 in FDA docket document FDA-2026-P-11717-0068, dated October 5, 2026.
  • The supplied record documents a glyphosate-exposure study attachment, not an FDA food-label, price, transport, or restaurant action.
  • No filer, lobbying disclosure, money figure, company beneficiary, ownership interest, or FDA decision deadline appears in the record provided.
  • No beneficiary-decider overlap or food-supply-chain effect is established by the supplied federal record.

The weekly grocery run is where big-picture food policy becomes tangible. It is in the price of a carton of eggs, the claims on a cereal box and the quiet hum of the refrigerated cases lining the aisles. Consumers make dozens of small decisions based on a complex web of information, trust and cost.

The rules governing that web are written far from the grocery store, in a language of dockets, attachments and administrative procedure that is often opaque. Sometimes, a single document surfaces from that world, sounding official and important. The challenge is knowing how to read it, and more often than not, understanding what it is not saying.

One such document, a single line item from a federal docket, points toward a complex debate over a widely used agricultural chemical. This digital breadcrumb is not the whole loaf. The record is not a new rule, a product recall or a change to a single food label.

It is an early stage action in a long administrative process. Understanding it requires separating documented fact from speculative noise. It is a lesson in how the machinery of government turns, one attachment at a time. The docket entry facts

The paper trail consists of a single entry on Regulations. gov, the digital public square where federal agencies post proposed rules and collect public comment. The record is officially titled "Attachment 66 - Ospina et al.

- 2022 - Exposure to glyphosate in the United States Data from the 20132014 National Health and Nutrition E." It is filed under docket document number FDA-2026-P-11717-0068 and carries a date of Oct. 5, 2026.

This title contains several critical facts. First, the document is an attachment. In a federal docket, which functions as a public case file, an attachment is equivalent to an exhibit entered into evidence.

Its submission means a party wants the decision maker to consider it. Its presence does not mean the decision maker finds it persuasive, relevant or accurate. It is not an order, a decision or a new policy from the Food and Drug Administration.

The title identifies the attachment as a specific piece of academic research, a 2022 paper by a group of authors led by Ospina on the topic of glyphosate exposure. This is not an internal FDA study. It is outside research submitted into the record.

The title specifies that the paper uses data from the 2013-2014 National Health and Nutrition Examination Survey (NHANES). This is a crucial detail. It means the research, while published in 2022, is based on health and nutrition data that is now over a decade old. In the world of science and regulation, data freshness is a significant factor in utility.

Finally, the docket number itself, FDA-2026-P-11717-0068, provides another clue. The FDA prefix confirms the agency responsible for the file. The P in the docket number typically stands for petition, suggesting this docket was opened in response to a formal request, known as a citizen petition, from an outside person or group asking the FDA to take a specific action. This attachment is likely one piece of evidence submitted to support that petition. The push for regulatory change

The submission of this academic study into a federal docket is an action designed to benefit the party who submitted it. While the record does not name the petitioner, the subject matter, glyphosate, points to a clear divide of interests. A change in glyphosate regulation would create distinct winners and losers across the food and agriculture sectors.

Beneficiaries of the current regulatory framework include the agricultural technology companies that manufacture and sell glyphosate and the farmers who use it. A change in rules could increase operational costs or limit product use for those operations. Downstream beneficiaries of the status quo include grain processors and food manufacturers who rely on a consistent and affordable supply of crops grown using this chemical. Any regulatory disruption that affects supply chains presents financial risk.

Conversely, the primary beneficiaries of a potential rule change, and therefore the likely party behind a petition like this, fall into a different camp. These include environmental organizations, consumer health advocacy groups and companies in the organic food industry. For these groups, stricter regulation or new labeling requirements for glyphosate would represent a policy victory. Companies that produce or sell alternatives to glyphosate, or market products as glyphosate-free, would also gain a direct commercial advantage from any rule that casts doubt on the chemical's safety or restricts its use.

The act of submitting the Ospina et al. study is a move to influence the FDA. The petitioner benefits by placing chosen scientific evidence into the official administrative record, creating a basis for the agency to act on its request. The benefit is procedural: the petitioner is building a case file to compel a decision from the regulator. The Food and Drug Administration's authority

The ultimate decider in this process is the Food and Drug Administration. The docket number prefix confirms the agency's jurisdiction. Specifically, power over food safety and labeling issues rests within the FDA's Center for Food Safety and Applied Nutrition (CFSAN). This office is staffed with scientists, statisticians and policy analysts who evaluate the safety of substances in food and the accuracy of labeling.

The FDA's power is not absolute. Authority is granted by laws passed by Congress, such as the Federal Food, Drug, and Cosmetic Act. The decision-making process is controlled by the Administrative Procedure Act (APA). The APA mandates a slow, deliberate and public process for creating new regulations. The agency cannot simply decide to change a rule based on a single study.

If a citizen petition is filed, the FDA is legally obligated to review it. CFSAN staff evaluate the petition and all supporting evidence, including Attachment 66. They weigh the submitted science against the larger body of scientific literature, existing regulations, international standards and the agency's statutory mandate.

Should the agency find the petition compelling enough to consider a new rule, this would trigger a lengthy public process. The FDA would first draft a Proposed Rule, complete with a detailed scientific justification and an economic analysis of potential impact. That proposal would then be published in the Federal Register, opening a formal public comment period where any interested party can submit data and arguments.

The agency must, by law, read and consider every comment. Only after this process can the FDA issue a Final Rule. This entire cycle, from petition to final rule, can take many years to complete.

The FDA's power lies not in swift action, but in its methodical, evidence-based regulatory process. An academic study connects two federal agencies

The supplied record documents a clear point of overlap: an outside party, the petitioner, is engaging directly with the decision maker, the FDA, by submitting evidence into its official docket. This is the fundamental interaction of the regulatory state, where interested parties formally petition the government for action.

The record also reveals an overlap involving multiple government bodies. The evidence itself, the 2022 Ospina et al. study, is based on data from the 2013-2014 National Health and Nutrition Examination Survey. NHANES is a major program of the National Center for Health Statistics, which is part of the Centers for Disease Control and Prevention (CDC).

This creates a documented, cross-agency sequence. One federal agency, the CDC, funded and collected national health data. Years later, academic researchers used this publicly available government data to produce a study. Now, that academic work is being submitted to a different federal agency, the FDA, as evidence in an attempt to persuade it to change a federal regulation.

This demonstrates how data generated by one part of the federal government can become a tool for advocacy directed at another. The petitioner is leveraging the scientific authority of a CDC dataset to make a case before the FDA. The record does not show any direct collaboration or contract between these agencies related to this specific docket. It shows the pathway of the information itself, from one agency's data collection to another agency's regulatory consideration. No financial disclosures in the record

The forensic standard requires an accounting of the money involved, including award amounts, contract values, lobbying expenditures or other financial figures.

The single record supplied, the docket entry for Attachment 66, contains no such financial information. The Regulations.gov filing does not disclose who funded the Ospina et al. study. It does not list contracts or grants related to the research. It does not provide a value for the petition or state how much money, if any, the petitioner spent on legal or scientific support.

Based strictly on the provided documentation, there are no financial figures to report. A complete financial picture would require access to other records not provided, such as funding disclosures in the original academic journal article, lobbying disclosure databases or the petitioner's organizational records. Without those documents, any statement about money would be speculation. A decade of data leads to a filing

The sequence of events is a critical component of the story. The dates provided in the record establish a clear chronology that spans more than a decade.

In 2013 and 2014, the Centers for Disease Control and Prevention, through its National Health and Nutrition Examination Survey, collected raw urine and health data from the U.S. population. This is the origin point for the data used in the study.

In 2022, eight years after data collection concluded, the study "Exposure to glyphosate in the United States" by Ospina et al. was published. This establishes a significant lag between when the biological samples were taken and when the analysis was made public.

After 2022, a citizen petition was filed with the Food and Drug Administration, requesting action related to glyphosate. This action opened docket number FDA-2026-P-11717.

On Oct. 5, 2026, according to the Regulations.gov entry, the Ospina et al. study was officially entered into the docket as Attachment 66.

This timeline establishes that the evidence entered into the record in 2026 is based on a 2022 analysis of data from 2013 and 2014. The data is more than 12 years old at the time of the filing. This time lag is a documented fact that would be a key consideration for agency scientists evaluating the study's relevance to current exposure levels. A filing is an activity, not a verdict

It is critical to separate what this federal record establishes from what it does not. An administrative filing is a record of an activity, not proof of wrongdoing or a signal of a predetermined outcome.

1. An unknown party filed a citizen petition with the FDA concerning glyphosate.

2. On Oct. 5, 2026, a 2022 academic study by Ospina et al. was submitted as Attachment 66 to the docket for that petition.

3. The study uses data from the CDC's 2013-2014 NHANES survey.

These are the established facts, documented by the entry in the Regulations.gov system.

The record does not prove the validity of the study. The attachment's presence in the docket does not mean the FDA or any other government body validated its methods, agrees with its conclusions or finds it scientifically sound. It is simply a piece of submitted evidence.

More from the Foodie Pundit Newsroom

Permalink